Abingworth LLP
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, France, Italy, Denmark, Switzerland, Spain, South Korea, Ireland, Netherlands, New Zealand, Portugal, Sweden, Belgium, Norway, Finland
Industries Focus
- Life Sciences
- Healthcare Services
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Immunology
- Genomics
- Medical Technology
- Healthcare IT
- Ophthalmology
- Orthopedics
- Pulmonology
- Rheumatology
- Dermatology
Investment Size:
3,000,000 to 100,000,000 USD
Investor Details Founded: 1973
Abingworth LLP is a distinguished international investment firm specializing in the life sciences and healthcare sectors. Founded in 1973, the firm has a long-standing reputation for supporting innovative companies at various stages of development, from early-stage startups to late-stage growth enterprises. Abingworth's investment portfolio spans biotechnology, pharmaceuticals, medical devices, and healthcare services, reflecting its commitment to advancing cutting-edge technologies and treatments. With offices in London, Menlo Park, and Boston, Abingworth leverages its transatlantic presence to identify and invest in promising opportunities worldwide.
The firm's investment strategy encompasses seed and early-stage investments, development-stage funding, and clinical co-development partnerships. Abingworth has successfully deployed over $3 billion in equity across 179 life sciences companies through 14 dedicated life sciences funds. Notably, 73 portfolio companies have transitioned onto the public markets through initial public offerings (IPOs), and 46 companies have undergone mergers or acquisitions. Additionally, 26 new medicines developed by companies funded by Abingworth have been approved by the US Food & Drug Administration in the past nine years.
In August 2022, Abingworth was acquired by The Carlyle Group, enhancing its capabilities and reach in the global life sciences market. This acquisition enables Carlyle and Abingworth to operate across the full risk-return spectrum of life sciences and healthcare investing, from venture capital to buyouts, and to continue their longstanding efforts to be an important part of the solution in healthcare. The combined entity aims to provide comprehensive support to life sciences companies, from early-stage development through to commercialization, leveraging a broad range of expertise and resources to drive innovation and improve patient outcomes.
Requirements
- Innovative therapeutics
- Medical devices
- Diagnostics
- Healthcare services
- Strong management teams
- Scalable business models
- Clear regulatory pathways
- Potential for significant patient impact
- Alignment with Abingworth's strategic focus areas
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Dicerna Pharmaceuticals
- Clovis Oncology
- Algeta
- Avila Therapeutics
- Syntaxin Ltd
- Effector Therapeutics
- Avedro
- Gensight Biologics
- Jasper Therapeutics
- AdvanCell
- Solve Therapeutics
Mentioned In
-
$99.00
-
$24.95
-
$19.95
-
$24.95
-
$19.95
-
$49.95
-
$19.95
-
$39.95
-
$99.00
-
$245.00
Claim this Investor
Are you an official representative of Abingworth LLP?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim